Glaukos Announces Participation in J.P. Morgan Healthcare Conference

About this update from Glaukos Corporation

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2774,"height":518,"url":"https://media.zenfs.com/en/business-wire.com/3da7a823357030aa2fa4cb92dba4a662"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/X2DxtQU7bERkYaYcLKcs1A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE3OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3da7a823357030aa2fa4cb92dba4a662","width":960,"height":179},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/pkLb0k9sbrGGcBaSLloI.Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00NDg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/3da7a823357030aa2fa4cb92dba4a662","width":1200,"height":224}},"lazy":false},{"type":"text","content":"ALISO VIEJO, Calif., December 16, 2025--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 4:30 p.m. PT in San Francisco, CA.","length":433,"tagName":"p"},{"type":"text","content":"A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.","length":162,"tagName":"p"},{"type":"text","content":"About Glaukos","length":13,"tagName":"p"},{"type":"text","content":"Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continu...

More updates from Glaukos Corporation